This episode explores the future of skin biomarkers. Featuring insights from Simon Grant, CEO of Ascilion, and Théo Boyer, Senior Project Coordinator at Indero, the episode examines how dermal interstitial fluid (d-ISF) could revolutionize dermatology. Our guests illuminate the potential of ISF sampling, paving the way for more personalized and innovative approaches to care.
All content for Phase Forward is the property of Podcast Series hosted by Valerie Coveney and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode explores the future of skin biomarkers. Featuring insights from Simon Grant, CEO of Ascilion, and Théo Boyer, Senior Project Coordinator at Indero, the episode examines how dermal interstitial fluid (d-ISF) could revolutionize dermatology. Our guests illuminate the potential of ISF sampling, paving the way for more personalized and innovative approaches to care.
Episode 35: PTCA – Speaking the Same Language: How Patient Organizations and Sponsors Can Align in Clinical Trials
Phase Forward
10 minutes 27 seconds
2 months ago
Episode 35: PTCA – Speaking the Same Language: How Patient Organizations and Sponsors Can Align in Clinical Trials
In this episode of Phase Forward, Hubert Godziatkowski, founder of the Polish Atopic Disease Association (PTCA), shares how patient organizations can reshape clinical trials. With over 800,000 people in Poland affected by atopic dermatitis, PTCA is working to improve clarity in consent forms, promote ethical oversight, and build trust between sponsors and patients. The conversation explores PTCA's review of consent forms, the importance of early collaboration, and the role of advocacy groups in improving recruitment and trial accessibility.
Phase Forward
This episode explores the future of skin biomarkers. Featuring insights from Simon Grant, CEO of Ascilion, and Théo Boyer, Senior Project Coordinator at Indero, the episode examines how dermal interstitial fluid (d-ISF) could revolutionize dermatology. Our guests illuminate the potential of ISF sampling, paving the way for more personalized and innovative approaches to care.
